Related Experiment Video

Updated: Jul 14, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Fusion protein containing SH3 domain of c-Abl induces hepatocarcinoma cells to apoptosis

Ji Kai Yin1, Ying Min Liang, Xian Li He

  • 1Department of General Surgery, Tangdu Hospital of Fourth Miliatry Medical University, Xi'an City, China.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|June 2, 2007
PubMed
Abstract

Insights

A novel fusion protein, PTD-BCR/ABL SH3, effectively inhibits hepatocarcinoma cell growth by inducing apoptosis. This protein demonstrated significant therapeutic effects in both in vitro and in vivo models, offering a potential new treatment for liver cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) remains a significant global health challenge.
  • Novel therapeutic strategies targeting cancer cells are urgently needed.
  • The PTD-BCR/ABL SH3 fusion protein combines HIV-1 TAT and BCR-ABL SH3 domains.

Purpose of the Study:

  • To investigate the biological behavior of the PTD-BCR/ABL SH3 fusion protein in hepatocarcinoma cells.
  • To evaluate the in vitro and in vivo anti-cancer activity of PTD-BCR/ABL SH3.

Main Methods:

  • In vitro studies involved coculturing HepG-2 cells with PTD-BCR/ABL SH3, followed by immunocytochemistry, light and electron microscopy, MTT assays, DNA laddering, and TUNEL staining.
  • In vivo studies utilized nude mice bearing HepG-2 tumors to assess the fusion protein's antitumor efficacy.

Main Results:

  • PTD-BCR/ABL SH3 successfully entered HepG-2 cells and localized in the nucleus.
  • The fusion protein induced significant apoptosis in HepG-2 cells, demonstrating high cytotoxicity.
  • In vivo, PTD-BCR/ABL SH3 markedly reduced tumor growth speed and prolonged survival time in mice without observable toxicity in major organs.

Conclusions:

  • PTD-BCR/ABL SH3 fusion protein exhibits potent inhibitory activity against hepatocarcinoma HepG-2 cells through apoptosis induction.
  • The fusion protein demonstrates promising therapeutic effects in vivo, suggesting its potential as an anti-liver cancer agent.

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...